



**Technology:** Insulin glargine is a long-acting recombinant human insulin analog that helps to control blood sugar levels in patients with diabetes.

## Insulin Glargine Timeline



## Insulin Glargine Challenged Claim Types in IPR and Litigation\*



\*Litigation Defendants alleged to infringe at least these claims in complaints/amended complaints.

# Spotlight On: Insulin Glargine

December 31, 2018

	<i>Sanofi v. Eli Lilly</i> 1:14-cv-00113 (D. Del.) Settled	<i>Sanofi v. Eli Lilly</i> 1:14-cv-00884 (D. Del.) Settled	<i>Sanofi v. Merck</i> 1:16-cv-00812 (D. Del.) Stipulated dismissal	<i>Sanofi v. Merck</i> 2:17-cv-05914 (D.N.J.) Stipulated dismissal	<i>Sanofi v. Mylan</i> 2:17-cv-09105 (D.N.J.) Ongoing	<i>Biocon &amp; Mylan v. Sanofi</i> IPR2017-01526 FWD (All instituted claims unpatentable)	<i>Biocon &amp; Mylan v. Sanofi</i> IPR2017-01528 FWD (All instituted claims unpatentable)	<i>Biocon &amp; Mylan v. Sanofi</i> IPR2018-01670 Awaiting institution decision	<i>Biocon &amp; Mylan v. Sanofi</i> IPR2018-01675 IPR2018-01676 Awaiting institution decision	<i>Biocon &amp; Mylan v. Sanofi</i> IPR2018-01677 Terminated prior to institution decision; Refiled as IPR2019-00122	<i>Biocon &amp; Mylan v. Sanofi</i> IPR2018-01678 IPR2018-01679 Awaiting institution decision
7,476,652	x	x	x	x	x	x					
7,713,930	x	x	x	x	x		x				
7,918,833		x	x		x						
8,512,297		x	x		x						
8,556,864	x	x	x		x						
8,603,044	x	x	x		x				x		
8,679,069	x	x	x		x			x			
8,992,486			x		x					x	x
9,011,391			x		x						
9,233,211			x		x					<i>Biocon &amp; Mylan v. Sanofi</i> IPR2018-01680 IPR2018-01682 IPR2018-01696 Awaiting institution decision	<i>Biocon &amp; Mylan v. Sanofi</i> IPR2018-01684 Awaiting institution decision
9,408,979					x						
9,457,152			x								
9,486,587			x								
9,526,844			x		x					x	
9,533,105			x		x						
9,561,331					x						
9,592,348			x								
9,604,008			x		x						x
9,604,009					x						
9,610,409					x						
9,623,189					x						